The firm, based in Glasgow in Scotland and Boston, US, says this programme simplifies the benefits of miRNA analysis and profiling to support timely decision making within clinical research. The new multiple miRNA biomarkers can be used to determine the efficacy of targeted drugs, in major therapeutic areas and when developing companion biomarker strategies for future clinical development.
Companion biomarkers are the most recent extension of microRNA technology and are set to provide valuable clinical data to guide both pre-clinical and clinical studies.
The firm says the system will use miRNA to identify highly discriminatory biomarkers, which, in turn, will guide patient prognosis, the selection of appropriate drug treatment, and monitoring of drug response.
